PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 8, 20260 citationsOpen Access

GPS1 Exon 9 Mutations Represent a Rare Genetic Event in Penile Squamous Cell Carcinoma Pathogenesis

View Full Paper
LTLars TögelFriedrich-Alexander-Universität Erlangen-NürnbergFEFelix ElsnerFriedrich-Alexander-Universität Erlangen-NürnbergOWOlaf WendlerFriedrich-Alexander-Universität Erlangen-Nürnberg

Key Points

  • This research aims to investigate the frequency and impact of GPS1 exon 9 mutations in penile squamous cell carcinoma (PSCC).
  • Conducted genomic profiling of a cohort of 106 PSCC cases.
  • Analyzed the occurrence of GPS1 mutations and alterations in exon 9.
  • Investigated functional implications of identified mutations.
  • Observed two novel GPS1 alterations in exon 9 in 1.9% of cases: p.S372F and p.A375D.
  • Previously reported GPS1 mutations p.D382H and p.M384I were not present in the cohort.
  • Non-recurrent nature of reported alterations suggests limited oncogenic potential in PSCC.

Abstract

Penile squamous cell carcinoma (PSCC) is rare, but a biologically aggressive malignancy. Recent comprehensive genomic profiling (CPG) efforts revealed the underlying genomic landscape of PSCC, identifying TP53, TERT, CDKN2A, PIK3CA, NOTCH1, and FAT1 as frequently altered genes with potential roles in penile oncogenesis. In addition, recurrent mutations encoded in the GPS1 gene have been observed in 7.4% of cases in a particular PSCC cohort. Functional studies demonstrated loss of function due to GPS1 Exon 9 missense mutations, proposing a possible role for these alterations as oncogenic driver events in PSCC. However, no other study confirmed the occurrence of GPS1 gene mutations in PSCC. To elucidate the biological function of GPS1 exon 9 mutations in PSCC pathogenesis, we utilized a comprehensive in-house cohort of 106 PSCC cases to explore their frequency and occurrence. Albeit, the previously reported GPS1 mutations p.D382H and p.M384I were not observed in this large cohort of PSCC cases; this analysis, however, revealed two novel GPS1 alterations in exon 9 in two (1.9%) of the analyzed cases: p.S372F (c.1115C>T) and p.A375D (c.1124C>A). This observation suggests that GPS1 exon 9 sequence is a target of genetic alteration during PSCC pathogenesis. However, the non-recurrent nature of these alterations indicates that they are unlikely to represent oncogenic drivers in this disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tögel et al. (2026) studied this question.

synapsesocial.com/papers/69ada8cfbc08abd80d5bc1b2https://doi.org/10.3390/ijms27052460
Ask AI
Helpful
Bookmark
Share
View Full Paper